News

Probiodrug and Crossbeta Extend Alzheimer’s Biomarker Partnership

Probiodrug and Crossbeta Biosciences are extending a partnership that Probiodrug believes will help it continue developing a potential Alzheimer’s therapy. Under the partnership, established in 2016, the companies are using a proprietary Crossbeta technology to try to create biomarkers specific to Alzheimer’s as opposed to   neurodegenerative diseases in general.

MIT Team Reveals What Happens to Brain Immune Cells During Alzheimer’s Development

Massachusetts Institute of Technology researchers have found that Alzheimer’s disease causes microglia — the immune cells that normally protect brain cells from damage — to change their behavior and instead promote a pro-inflammatory immune response. Their study, “Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution,” appeared in…